H. pylori Treatment Cuts Colorectal Cancer Risk by Half Over 30 Years
Two large randomized trial cohorts show H. pylori infection raises colorectal cancer risk, and eradication therapy offers lasting protection.
Summary
Two major Chinese randomized trial cohorts followed participants for up to 29 years and found that Helicobacter pylori infection significantly raises colorectal cancer risk. Untreated H. pylori-positive individuals had up to a three-fold higher risk compared to uninfected individuals. Antibiotic eradication therapy was associated with a 53–62% reduction in colorectal cancer risk over nearly three decades. The protective benefit was especially strong in people who successfully cleared the infection and those genetically predisposed to colorectal cancer. Specific H. pylori virulence factors — including the antigen CagA — also influenced cancer risk. These findings suggest H. pylori eradication could be an important preventive strategy, particularly for high-risk individuals identified through genetic screening.
Detailed Summary
Colorectal cancer is a leading cause of cancer death worldwide, and identifying modifiable risk factors is a major public health priority. While H. pylori has long been linked to stomach cancer, its role in colorectal cancer has been debated. This study provides some of the strongest evidence yet that the connection is real — and that treating the infection may meaningfully reduce risk.
Researchers drew on two randomized trial cohorts in China: the Shandong Intervention Trial (SIT, n=3,365, followed for up to 29.4 years) and the Mass Intervention Trial in Linqu (MITS, n=180,284, followed for up to 13.8 years). They examined colorectal cancer incidence in relation to H. pylori infection status and antibiotic treatment, and in the MITS cohort, further assessed whether host genetic predisposition or specific H. pylori virulence factors modified the risk.
Key findings were striking. Untreated H. pylori-positive individuals faced significantly elevated colorectal cancer risk — nearly three-fold higher in SIT and 27% higher in MITS compared to uninfected individuals. In SIT, H. pylori treatment was associated with a 53% reduction in colorectal cancer risk over nearly three decades, with successful eradication yielding a 62% reduction. In MITS, no overall benefit was observed at the 13.8-year follow-up, but individuals in the top decile of polygenic risk scores and those seropositive for specific virulence antigens (CagA, HpaA, Omp, HP0305) showed a clear protective effect from treatment.
The clinical implications are significant. Clinicians may want to consider H. pylori eradication not only for gastric cancer prevention but as a potential colorectal cancer prevention strategy — especially in genetically high-risk patients. Polygenic risk scores and virulence factor serology could help identify who benefits most.
Caveats include that colorectal cancer outcomes were post hoc observational analyses within trial cohorts, not pre-specified endpoints. The two trials also showed differing results, possibly due to follow-up duration differences. Additionally, this summary is based on the abstract only.
Key Findings
- Untreated H. pylori infection was associated with up to 3x higher colorectal cancer risk across two large cohorts.
- H. pylori eradication reduced colorectal cancer risk by 53–62% over nearly 30 years of follow-up in SIT.
- Successful H. pylori eradication provided greater protection than treatment attempts with incomplete clearance.
- Individuals in the top genetic risk decile (polygenic risk score) benefited most from H. pylori treatment.
- Seropositivity for four H. pylori antigens (CagA, HpaA, Omp, HP0305) identified highest-risk individuals.
Methodology
The study pooled data from two randomized trial cohorts in China (SIT: n=3,365; MITS: n=180,284) with follow-up periods of up to 29.4 and 13.8 years respectively. Within MITS, a case-cohort design was used to evaluate colorectal cancer risk by H. pylori virulence factor serology and polygenic risk scores. Colorectal cancer incidence was a post hoc observational endpoint, not a pre-specified primary trial outcome.
Study Limitations
Colorectal cancer outcomes were post hoc analyses rather than pre-specified trial endpoints, limiting causal inference. The two cohorts showed divergent treatment benefit results, possibly reflecting differences in follow-up duration or population characteristics. This summary is based on the abstract only and full methodology and subgroup data were not available for review.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: